Results 71 to 80 of about 87,925 (315)
JAMA dermatology, 2019 Importance Dermatofibrosarcoma protuberans (DFSP) has the potential for local destruction and recurrence, although it carries a low risk of metastasis.
C. Navarrete-Dechent +4 more
semanticscholar +1 more source
A Knowledge‐Guided Graph Learning Approach Bridging Phenotype‐ and Target‐Based Drug Discovery
Advanced Science, EarlyView.Knowledge‐Guided Drug Relational Predictor (KGDRP), a graph representation learning approach, effectively integrates multiple omics data, including biological network data, gene expression data, and sequence data that incorporates chemical molecular structures.
Qing Ye +10 more
wiley +1 more source
Indian Journal of Pharmacology, 2010 Drug-induced pancreatitis is a rare but serious complication of many drugs, some of which have been well documented. Here we present a case of a middle-aged man with chronic myeloid leukemia who developed acute pancreatitis after being initiated on imatinib mesylate. The case history, the pharmacodynamics, uses, and adverse effects of imatinib mesylate
Varma, Mahesh R. +3 more
openaire +4 more sources
RAB3B Dictates mTORC1/S6 Signaling in Chordoma and Predicts Response to mTORC1‐Targeted Therapy
Advanced Science, EarlyView.RAB3B is unveiled as a prominent oncogenic regulator in chordoma, which can block the DUSP12‐mediated dephosphorylation of p‐S6 (S235/236). The combination of RAB3B and p‐S6 indicates a good prognostic value and predicts mTORC1 inhibitors response for chordoma patients.
Jianxuan Gao +15 more
wiley +1 more source
Imatinib-induced hepatitis treated by corticosteroids in a patient with metastatic gastrointestinal stromal tumor [PDF]
Yeungnam University Journal of Medicine, 2019 Imatinib mesylate is currently used as the first-line treatment for metastatic gastrointestinal stromal tumors (GISTs). Imatinib-induced hepatotoxicity in patients with GIST is very rare.
Min Kyu Kang +2 more
doaj +1 more source
JAMA Oncology, 2018 Importance Three years of adjuvant imatinib mesylate therapy is associated with reduced recurrence rates and improved overall survival in patients with high-risk primary gastrointestinal stromal tumor (GIST) compared with patients who receive 1 year of ...
Chandrajit P. Raut +8 more
semanticscholar +1 more source
Do you get the GIST? Successful resection of a giant 3.5 kg gastrointestinal stromal tumour
, 2022 ANZ Journal of Surgery, Volume 92, Issue 12, Page 3356-3359, December 2022.
Luca Borruso +5 more
wiley +1 more source
Journal of Clinical Oncology, 2007 PURPOSE Response Evaluation Criteria in Solid Tumors (RECIST) are insensitive in evaluating gastrointestinal stromal tumors (GISTs) treated with imatinib.
Haesun Choi +8 more
semanticscholar +1 more source
Imatinib and hypophosphatemia: Case report and review of literature
Journal of Oncological Sciences, 2017 Imatinib mesylate is a potent inhibitor of the BCR-Abl kinases, c-Kit, PDGFR, and fms. Imatinib used for treatment of chronic myeloid leukemia and gastrointestinal stromal tumor. Imatinib has been well tolerated.
Erdem Şen, İrem Öner, Özlem Ata
doaj +1 more source
Annals of Surgery, 2019 Supplemental Digital Content is available in the text Objective: To characterize the results of surgery for gastrointestinal stromal tumor (GIST) in the pre and post-imatinib eras at a single institution and to identify current prognostic ...
M. Cavnar +13 more
semanticscholar +1 more source